Novel Therapies in APOL1-Mediated Kidney Disease: From Molecular Pathways to Therapeutic Options

Apolipoprotein L1 (APOL1) high-risk variants confer an increased risk for the development and progression of kidney disease among individuals of recent African ancestry. Over the past several years, significant progress has been made in understanding the pathogenesis of APOL1-mediated kidney disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasquez-Rios, George, De Cos, Marina, Campbell, Kirk N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658239/
https://www.ncbi.nlm.nih.gov/pubmed/38025220
http://dx.doi.org/10.1016/j.ekir.2023.08.028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658239/
https://www.ncbi.nlm.nih.gov/pubmed/38025220
http://dx.doi.org/10.1016/j.ekir.2023.08.028

Ejemplares similares